AU2002336408B2 - Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives - Google Patents

Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives Download PDF

Info

Publication number
AU2002336408B2
AU2002336408B2 AU2002336408A AU2002336408A AU2002336408B2 AU 2002336408 B2 AU2002336408 B2 AU 2002336408B2 AU 2002336408 A AU2002336408 A AU 2002336408A AU 2002336408 A AU2002336408 A AU 2002336408A AU 2002336408 B2 AU2002336408 B2 AU 2002336408B2
Authority
AU
Australia
Prior art keywords
polypeptide
composition
variant
amino acid
damage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002336408A
Other languages
English (en)
Other versions
AU2002336408A1 (en
Inventor
Jack Finkelstein Jr
Allan L. Goldstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RegeneRx Biopharmaceuticals Inc
Original Assignee
RegeneRx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RegeneRx Biopharmaceuticals Inc filed Critical RegeneRx Biopharmaceuticals Inc
Publication of AU2002336408A1 publication Critical patent/AU2002336408A1/en
Application granted granted Critical
Publication of AU2002336408B2 publication Critical patent/AU2002336408B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2002336408A 2001-08-29 2002-08-29 Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives Ceased AU2002336408B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31534701P 2001-08-29 2001-08-29
US60/315,347 2001-08-29
PCT/US2002/027520 WO2003020215A2 (en) 2001-08-29 2002-08-29 Methods of treating mycocardial event related coditions with thymosin beta 4

Publications (2)

Publication Number Publication Date
AU2002336408A1 AU2002336408A1 (en) 2003-06-05
AU2002336408B2 true AU2002336408B2 (en) 2006-12-21

Family

ID=23223988

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002336408A Ceased AU2002336408B2 (en) 2001-08-29 2002-08-29 Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives

Country Status (8)

Country Link
US (1) US9056087B2 (enExample)
EP (1) EP1427432A4 (enExample)
JP (2) JP2005502672A (enExample)
CN (2) CN101549148A (enExample)
AU (1) AU2002336408B2 (enExample)
CA (1) CA2458883C (enExample)
MX (1) MXPA04001942A (enExample)
WO (1) WO2003020215A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2266595A3 (en) * 2002-02-06 2011-07-06 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
WO2006076254A2 (en) * 2005-01-11 2006-07-20 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing respiratory microbial infection of respiratory tissue
US20080051348A1 (en) * 2002-02-06 2008-02-28 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
CN1852727A (zh) * 2003-03-31 2006-10-25 雷金纳克斯生物制药公司 递送胸腺素β4、类似物、同工型和其它衍生物的组合物和方法
CA2532542A1 (en) * 2003-07-18 2005-01-27 Regenerx Biopharmaceuticals, Inc. Treatment or prevention of damage due to radiation exposure
US20090053194A1 (en) * 2003-12-22 2009-02-26 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent
WO2005087805A1 (en) * 2004-03-05 2005-09-22 Regenerx Biopharmaceuticals, Inc. Treating or preventing extracellular matrix build-up
JP2008510732A (ja) * 2004-08-20 2008-04-10 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 心臓組織の損傷を処置、予防、阻害、または緩和する方法
US7531318B2 (en) 2004-08-20 2009-05-12 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults
CA2612522A1 (en) * 2005-06-17 2006-12-28 Regenerx Biopharmaceuticals, Inc. Lkktet and/or lkktnt peptide compositions and methods
JP2009502938A (ja) * 2005-07-26 2009-01-29 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 鬱血性心不全が原因である組織の劣化、損傷、または破損を処置または予防する方法
WO2007014254A2 (en) * 2005-07-26 2007-02-01 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to hypertrophic muscle disease
CN100372572C (zh) * 2005-09-29 2008-03-05 北京诺思兰德生物技术有限责任公司 携带人胸腺素β4基因的重组质粒
US8399412B2 (en) * 2006-10-06 2013-03-19 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating NF-kappabeta or supressing NF-kappabeta-mediated actions
HUP0600814A3 (en) * 2006-10-27 2009-08-28 Biostatin Gyogyszerkutato Fejl Peptides for activation of angiogenesis, pharmaceutical compounds containing same and use of these compounds
MX2010010177A (es) * 2008-03-17 2012-08-23 Regenerx Biopharmaceuticals Fragmentos de beta timosina mejorada.
KR101297037B1 (ko) * 2010-03-26 2013-08-14 숙명여자대학교산학협력단 혈관신생촉진용 펩타이드 및 이의 용도
BR112013000923A2 (pt) * 2010-07-14 2016-05-17 Adistem Ltd método de tratamento de hiv ou aids
WO2012044783A2 (en) * 2010-09-30 2012-04-05 Regenerx Biopharmaceuticals, Inc. Method of achieving a thymosin beta 4 concentration in a human patient
JP6889771B2 (ja) * 2016-07-18 2021-06-18 リジェンツリー リミテッド ライアビリティ カンパニー ドライアイ症候群を治療する方法
WO2021225960A2 (en) * 2020-05-05 2021-11-11 Regenerx Biopharmaceuticals, Inc. Beta thymosin peptides for treating viral infections
CN111821424B (zh) * 2020-07-21 2023-03-31 广东海洋大学深圳研究院 胸腺素及其衍生物的应用和治疗抑郁症的药物
CN112023027B (zh) * 2020-07-21 2023-03-14 广东海洋大学 胸腺素或其衍生物的应用和治疗快感缺乏型抑郁症的药物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297276A (en) * 1979-03-23 1981-10-27 Hoffman-La Roche Inc. Thymosin beta 3 and beta 4
JPS61500431A (ja) 1982-12-09 1986-03-13 ビルトン，ジエラルド　エル． 傷治癒に有用な活性化され、安定化された酵素
US4543340A (en) 1983-04-07 1985-09-24 George Washington University Radioimmunoassay of thymosin β4
JPH02124815A (ja) 1987-10-29 1990-05-14 Takeda Chem Ind Ltd 血管形成促進剤
US5654267A (en) 1988-12-20 1997-08-05 La Jolla Cancer Research Center Cooperative combinations of ligands contained within a matrix
JPH03178988A (ja) 1989-09-14 1991-08-02 Takeda Chem Ind Ltd 生理活性物質ｔａｎ―８８３、その製造法および用途
CN1173991C (zh) 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
EP0725652A1 (en) 1993-10-07 1996-08-14 The George Washington University Medical Center METHOD OF TREATING SEPTIC SHOCK USING THYMOSIN $g(b) 4?
US5578570A (en) 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
AU3733295A (en) 1994-10-06 1996-05-02 Alpha 1 Biomedicals, Inc. Treatment of obstructive airway disease by administering thymosin beta 4, or coadministration of thymosin beta 4 and dnase i
US5663071A (en) 1996-06-17 1997-09-02 Children's Medical Center Corporation Human thymosin β 15 gene, protein and uses thereof
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
GB9806632D0 (en) 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
JP4301602B2 (ja) 1998-09-28 2009-07-22 株式会社マルハニチロ水産 血管内皮細胞増殖促進剤
PT1100529E (pt) 1998-07-30 2005-10-31 Us Gov Health & Human Serv A timosina beta 4 promove a preparacao de feridas
US7560280B2 (en) * 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Docs cited in WO 03/020215 *

Also Published As

Publication number Publication date
CA2458883A1 (en) 2003-03-13
EP1427432A4 (en) 2008-01-23
US9056087B2 (en) 2015-06-16
CA2458883C (en) 2017-11-28
JP2009221211A (ja) 2009-10-01
WO2003020215A2 (en) 2003-03-13
CN101549148A (zh) 2009-10-07
JP2005502672A (ja) 2005-01-27
WO2003020215A3 (en) 2004-03-25
CN1547480A (zh) 2004-11-17
EP1427432A2 (en) 2004-06-16
MXPA04001942A (es) 2004-07-23
US20040258680A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
AU2002336408B2 (en) Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives
AU2002336408A1 (en) Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives
JP2009046502A (ja) 皮膚状態の改善を促進するための組成物の製造のための、アミノ酸配列ｌｋｋｔｅｔを含む皮膚変性阻害ポリペプチドの使用
US20060246057A1 (en) Treatment or prevention of damage due to radiation exposure
AU2002309842B2 (en) Treating epidermlyosis bullosa with thymosin beta 4
EP1706136A2 (en) Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent
AU2002213513A1 (en) Inhibition or reversal of skin aging by actin-sequestering peptides
US8399609B2 (en) Treating or preventing extracellular matrix build-up
US20040067227A1 (en) Inhibition or reversal of skin aging by actin-sequestering peptides
AU2002309842A1 (en) Treating epidermlyosis bullosa with thymosin beta 4
HK1136216A (en) Use of polypeptides for preparing medicines of promoting the transformation of cardiac endothelial cells to mesenchymal cells
US20040170625A1 (en) Methods of treating Epidermolysis Bullosa and associated dermatological indications with thymosin beta 4, analogues, isoforms and other derivatives
WO2007014254A2 (en) Method of treating or preventing tissue deterioration, injury or damage due to hypertrophic muscle disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired